The Checkup by Singlecare

APRIL 5, 2024

That’s because the Food and Drug Administration (FDA) has approved it for Type 2 diabetes , while weight management is technically an off-label treatment. Health condition Insurance companies are much more likely to cover Ozempic when it’s prescribed for diabetes than for weight loss.

Insurance 78

Insurance Documentation Insurance Coverage FDA 78

The Checkup by Singlecare

DECEMBER 28, 2023

Weight loss is an off-label , non-FDA-approved use for Ozempic. Because Ozempic is currently approved by the FDA for only diabetes management, health insurance plans are unlikely to cover the prescription medication for off-label uses such as weight loss. In fact, in clinical trials, patients taking Ozempic were able to lose 10.9%

Insurance 104

Insurance Insurance Coverage FDA Documentation 104

The FDA Law Blog

MAY 15, 2023

States frequently review labels (and labeling) for animal food products. The CFI includes a list of common foods that “may be appropriate for use in animal food and serve as a tool for use during review of ingredients on an animal food label.” This document also describes an appeal procedure.

Labelling 45

Labelling Documentation FDA 45

The Checkup by Singlecare

APRIL 17, 2024

Mounjaro (tirzepatide) is an injectable medication prescribed for Type 2 diabetes mellitus, which some doctors may prescribe off-label for weight loss. Over 80 million Americans received Medicaid assistance in 2023, and it sometimes covers Mounjaro for diabetes treatment.

Insurance 98

Insurance Insurance Coverage Compounding Pharmacies Compounding 98

The Checkup by Singlecare

JANUARY 3, 2024

Ozempic (semaglutide) is touted as a “miracle drug” for its ability to lower blood sugar for people with Type 2 diabetes and off-label to help people with obesity reach a healthy weight. The benefits are well-known—and well-documented in the popular press—but what about the potential downsides? Are tiredness and fatigue one of them?

Dosage 105

Dosage Documentation Compounding Labelling 105

The Checkup by Singlecare

DECEMBER 1, 2023

Red Dye 40 is among the most commonly used artificial food dyes in the United States, and you might see it labeled under a different name on the products you consume. Regardless of what manufacturers label it as, there have been ties to specific negative side effects when ingested too frequently. FDA (2023) Is Red Dye 40 safe?

Labelling 52

Labelling FDA Documentation 52

The FDA Law Blog

JANUARY 1, 2024

Maybe that’s also why FDA last week publicized the highest number of important Warning Letters of the year (compared with prior releases in 2023). Perhaps FDA wanted us to remember 2023 as the year FDA succeeded in uncovering critical defects in drug and device manufacturing, and in critical trials. Terragene S.A., Terragene S.A.,

FDA 59

FDA Documentation Labelling 59

The FDA Law Blog

OCTOBER 10, 2023

By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — As we recently blogged , FDA released three draft guidance documents to help enhance the predictability, consistency, and transparency of the 510(k) program. One of these documents focuses on “ Evidentiary Expectations for 510(k) Implant Devices.”

Documentation 45

Documentation FDA Labelling Communication 45

The FDA Law Blog

OCTOBER 24, 2023

Mullen — As of October 1, 2023, all 510(k) submissions, unless exempted, must be submitted to FDA using the electronic Submission Template And Resource ( eSTAR ). On September 29, 2023, FDA released a draft guidance on Electronic Submission Template for Medical Device De Novo Requests. By Philip Won & Allyson B.

FDA 52

FDA Documentation Labelling 52

European Pharmaceutical Review

DECEMBER 20, 2023

In Q1 2023, the European Commission (EC) announced proposed changes to EU pharmaceutical legislation. In October 2023, the European Parliament (EP) proposed revisions to the European Commission proposals with diverging views on various topics set out through two documents. Internet] 2023. Internet] 2023.

Labelling 82

Labelling Documentation 82

The FDA Law Blog

MAY 8, 2023

a) , and related guidance documents (e.g., Post-market, manufacturers can make modifications consistent with the PCCP and document the modification in accordance with their quality system, without the need for a new marketing submission. See 21 CFR 807.81(a)(3) a)(3) and 21 CFR 814.39(a)

FDA 98

FDA Documentation Labelling 98

The FDA Law Blog

FEBRUARY 27, 2023

That emergency declaration is set to expire on May 11, 2023. 180 days past May 11, 2023) for those telemedicine relationships established during the COVID-19 emergency. Helpful practitioner prescribing guidance is set forth in a simplified document here. 21 U.S.C. § 802(54)(D)(i). Stay tuned.

Controlled Substances 59

Controlled Substances FDA Documentation Labelling 59

The FDA Law Blog

MAY 19, 2023

Serial testing was defined as testing symptomatic individuals twice over three days with at least 48 hours between tests, which is in accordance with study findings from the National Institute of Health referenced here and current EUA labeling for serial testing. Customer Support Help line).

Labelling 40

Labelling FDA Documentation 40

Pharmaceutical Technology

JULY 28, 2022

The TLR9 agonist is currently being investigated in the Phase III CONCLUDE trial (NCT04985968), with an expected study completion date of August 2023. This is an important population to target, as it is well-documented that a number of patients are intolerant or non-responsive to first-line biologics like infliximab or adalimumab.

Immunization 98

Immunization Documentation Labelling FDA 98

The Checkup by Singlecare

NOVEMBER 14, 2023

Be sure to read the labels of over-the-counter sleep aids and cold medications to look for the presence of diphenhydramine before taking more. Remember, diphenhydramine comes in products by MANY names, and you don’t want to double up, so read the labels carefully. They can help review for any interactions with other drugs being taken.

Labelling 52

Labelling Dosage Compounding Medication Labelling 52

European Pharmaceutical Review

JANUARY 25, 2024

Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. This document is revised from a version published in October 2023.

FDA 87

FDA Documentation Method Validation Packaging 87

The Checkup by Singlecare

JANUARY 23, 2024

There are many off-label uses of diltiazem as well. Diltiazem has documented interactions with many types of medications. It is best to avoid red yeast rice supplements or be diligent in reading the product labeling. Diltiazem and disease/CBD/illicit drugs/vitamins/herbal supplements/etc.

Labelling 52

Labelling Documentation 52

The FDA Law Blog

MARCH 27, 2023

Such codes need to be placed on device labels and packages to allow devices to be easily identified and tracked throughout their lifecycle, except where the rule provided for an exception or alternative. The compliance dates were first published in 2013, and subsequently updated in various guidance documents and regulations published by FDA.

Labelling 45

Labelling Packaging FDA Documentation 45

The FDA Law Blog

NOVEMBER 2, 2023

Lewis, Senior Regulatory Device & Biologics Expert — On October 20, 2023, FDA announced the availability of the final guidance authored by CBER titled “Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies.” Tobolowsky & Richard A. It finalized a draft guidance published in 2022.

FDA 59

FDA Packaging Documentation Labelling 59

The FDA Law Blog

FEBRUARY 21, 2024

The long-awaited final rule, which we last discussed in a July 2023 blog post and have tracked in our March 2023 and March 2022 posts, aims to harmonize quality management system requirements for medical devices with requirements set forth by other regulatory authorities around the world. Notably, Part 820 will look different.

FDA 59

FDA Labelling Packaging Documentation 59

pharmaphorum

MARCH 26, 2021

The GMP provisions require the EU and UK to recognise the other’s manufacturing facility inspections and accept its GMP documents. The sizeable gap in the TCA is the EU and UK’s failure to agree on mutual recognition of conformity assessments, approval bodies, product markings or labelling, other than the very limited provisions on GMP.

Documentation 101

Documentation Labelling 101

The FDA Law Blog

JULY 6, 2023

We now see that the proposed rule to “harmonize and modernize” the QSR with ISO13485:2016, creating the new QMSR, is on the Spring 2023 Unified Agenda (see here ). In fact, the priority designation for the final rule is labeled as “economically significant.” According to the Unified Agenda, the proposed rule is in the final rule stage.

FDA 52

FDA Documentation Labelling 52

The FDA Law Blog

FEBRUARY 28, 2023

The general structure of our submissions, and of many others that we have seen, is to have a document for each of the twenty sections and then to refer to other files, such as labeling and test reports, as attachments. Several sections of the eSTAR templates have questions that walk through related guidance documents.

Documentation 52

Documentation Labelling Communication FDA 52

The Checkup by Singlecare

JANUARY 18, 2024

Nutritional fact labels on products can identify if a food is high in magnesium. Check for the daily value of vitamin D on the Nutrition Fact Labels on food products. Magnesium-rich foods include seeds and nuts such as almonds, cashews, peanuts, pumpkin seeds, and chia seeds. Salmon, red meat, and eggs are naturally rich in vitamin D.

Medical Schools 52

Medical Schools Mayo Clinic Labelling Documentation 52

ISPE

JANUARY 11, 2023

Life-Cycle Approach to Cleaning Topical Drug Products Trudy Patterson Wed, 01/11/2023 - 10:17 Technical January / February 2023 Life-Cycle Approach to Cleaning Topical Drug Products Dijana Hadziselimovic Kamini I. A draft of these updates should be provided with the validation documentation and implemented upon successful execution.

Method Validation 52

Method Validation Documentation Packaging Compounding 52

The FDA Law Blog

OCTOBER 18, 2022

On October 17, 2022, FDA published the list of CDRH proposed guidances for FY 2023 (see here ). These are documents on the A-list, a list of prioritized documents that FDA intends to publish during FY2023. These are documents on the A-list, a list of prioritized documents that FDA intends to publish during FY2023.

Documentation 52

Documentation FDA Labelling 52

The FDA Law Blog

FEBRUARY 28, 2024

This is the third withdrawal of an accelerated approval FDA has performed, following Avastin in 2011 and Makena in 2023. In contrast , the two previous withdrawals, Makena in 2023 and Avastin in 2011, took 30 months and 11 months, respectively. On August 4, 2023, Oncopeptides submitted its appeal.

FDA 59

FDA Documentation Labelling 59

IDStewardship

MARCH 12, 2023

BCPS, BCIDP Article Posted 12 March 2023 As a pharmacist serving as a preceptor to students and residents in the area of infectious diseases since 2010, I have always been on the hunt for good infectious diseases journal articles for my learners to read. Authored by: Timothy P. Gauthier, Pharm.D.,

Medication Guidelines 296

Medication Guidelines Documentation Labelling Hospitals 296

ISPE

JULY 19, 2023

™ Is Gaining Momentum and Driving Innovation Trudy Patterson Wed, 07/19/2023 - 08:17 Online Exclusives July / August 2023 Pharma 4.0™ ™ Is Gaining Momentum and Driving Innovation Thomas ZIMMER, PhD 19 July 2023 The fifth Pharma 4.0™ The next important milestones for 2023 are the ISPE Pharma 4.0™ ISPE Pharma 4.0™

Documentation 98

Documentation FDA Labelling Communication 98

ISPE

JULY 10, 2023

ChatGPT, BARD, and Other Large Language Models Meet Regulated Pharma Trudy Patterson Mon, 07/10/2023 - 15:37 Technical July / August 2023 ChatGPT, BARD, and Other Large Language Models Meet Regulated Pharma Martin Heitmann, FRM Stefan MÜNCH Brandi M. The response by ChatGPT is marked as ChatGPT.

Labelling 52

Labelling Documentation Pharmaceutical Companies Pharmaceutical Companies 52

The FDA Law Blog

AUGUST 10, 2022

Because Jazz timely sued Avadel, the lawsuit triggered a 30-month stay, which effectively precludes final approval of the Lumryz NDA until the expiration of the patent in June 2023. Nor does FDA have the authority to look beyond the Lumryz labeling to its REMS document for a use that overlaps with the listed use code, Avadel argues.

FDA 52

FDA Labelling Documentation 52

ISPE

MAY 11, 2023

Enhanced Intervention Detection in Aseptic Fill Using AI/ML Trudy Patterson Thu, 05/11/2023 - 10:32 Technical May / June 2023 Enhanced Intervention Detection in Aseptic Fill Using AI/ML Michelle Vuolo Christoph Koeth Robert J. Vials are rejected or discarded when critical zone intrusion is detected during operator interventions.

Documentation 52

Documentation Labelling FDA 52

The FDA Law Blog

JANUARY 4, 2023

2617, the “ Consolidated Appropriations Act, 2023 ,” was signed into law by President Biden on December 29. The PIE Act, otherwise known as section 3630, “Facilitating Exchange of Product Information Prior to Approval” of H.R.

Communication 64

Communication FDA Labelling Documentation 64

The FDA Law Blog

FEBRUARY 22, 2023

The only exception for a modified device is when there were no changes to: the user interface; intended device users; intended device uses; intended use environment(s); training or labeling. as a de novo special control or in a guidance document for a specific device type).

FDA 64

FDA Documentation Labelling Hospitals 64

The FDA Law Blog

JANUARY 23, 2023

Livornese — Last month, Congress took a big step towards improving clinical trial diversity by requiring sponsors of most drug and device clinical studies to submit a diversity action plan when they submit key trial documents to the Food and Drug Administration (FDA). by the end of 2023).

FDA 59

FDA Documentation Labelling 59

The Thyroid Pharmacist

JULY 14, 2023

Individual doctors may still be able to utilize this therapy with their patients as an “off-label” use. Remission of Hashimoto’s thyroiditis in a twelve-year-old girl with thyroid changes documented by ultrasonography. Accessed May 25, 2023. Accessed June 9, 2023. References [1] Nanan R, Wall JR. doi:10.1089/thy.2010.0102;

Dosage 97

Dosage FDA Immunization Documentation 97

The FDA Law Blog

OCTOBER 2, 2023

The new guidance is one of three policy documents dedicated to explaining FDA’s interpretation of this statutory authority and their approach to exercising scientific judgment in evaluating drug effectiveness. We are heartened to see that this latest guidance reflects many of the advances we observed in practice since 2019.

FDA 64

FDA Documentation Labelling Medical Records 64